Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab can be used for advanced or metastatic solid tumors research[1].
[1]. Hernandez-Guerrero T, et al: Not Ready for Prime Time. Clin Cancer Res. 2022 Sep 15;28(18):3905-3907.
















